|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_ForwardLookingEvaluationsAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
05.03.2020
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
In the January-February period of 2020, while both our domestic (20%) and foreign medical tourism (26%) revenue grew above our expectations, total hospital revenue increased by 21%. Although there was a slight decline in our foreign medical tourism revenues due to travel restrictions originating from COVID-19 in March, it is observed that strong domestic revenue growth compensates this weakness.
In addition, SSI price list was updated on March 3 to be effective after March 11. The new SSI prices, which came into effect in March, are expected to support domestic hospital revenue positively and compensate for losses that may occur in foreign medical tourism revenue. Our annual financial guidance announced on March 5, 2020 does not include the effect of updated SSI prices. In this context, we maintain our expectation of 18% revenue and 25% EBITDA growth in 2020.
|
||||||||